SenesTech to Participate at Lytham Partners Spring 2023 Investor Conference on May 18, 2023

PHOENIX, May 15, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) (www.senestech.com) the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, ContraPest^®, today announced Joel Fruendt, CEO, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2023 Investor Conference, taking place virtually on May 18, 2023.

The Company's webcasted fireside chat will be available for viewing at 9:00am ET on Thursday, May 18, 2023, on the Company's website at http://senestech.investorroom.com/ or https://wsw.com/webcast/lytham8/snes/2055375. The webcast will also be archived and available for replay.

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [email protected] or register at https://www.lythampartners.com/spring2023invreg/. 

We are "The Pest Control Difference" for the 21st century. We are rodent fertility control specialists fueled by our passion to create a healthy environment by virtually eliminating rodent pest populations. We keep an inescapable truth in mind: 2 rats and their descendants can be responsible for the birth of up to 15,000 pups in a year. We invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats. ContraPest fits seamlessly into all integrated pest management programs, greatly improving the overall goal of effective rat management. We strive for clean cities, efficient businesses, and happy households ? with a product that was designed to be effective and sustainable without killing rats. At SenesTech , we don't just eliminate rats. We make a better world.

For more information visit https://senestech.com/ and https://contrapeststore.com.

The foregoing paragraphs contain forward-looking statements that involve estimates, assumptions, risks and uncertainties. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. "Forward-looking statements" may be preceded by words such as "may," "future," "plan" or "planned," "will," "should," "expected," "anticipates," "continue," "eventually," "believes," or "projected." Forward-looking statements include statements concerning the potential impact and effects of the COVID-19 pandemic on the Company's business, results of operations and financial performance; any measures the Company has and may take in response to COVID-19 and any expectations the Company may have with respect thereto; the Company's strategy and target marketing and markets; continuing the Company's vision; expected benefits of the Company's initiatives and continuation of those initiatives; deployment of the Company's product; the continuation or expansion of the use of ContraPest; demand for ContraPest; the Company's expectation regarding costs, expenses and cash and continuing its cost improvement plan; future financial results; and the Company's execution of its strategic business plan.

CONTACT: 

Investor: Robert Blum, Lytham Partners, LLC, 602-889-9700, [email protected]

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143

SOURCE SenesTech, Inc.